Ovarian Cancer

>

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Latest News

Rowan T. Chlebowski, MD, PhD
Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence

May 23rd 2024

Treatment with CEE alone was associated with increased ovarian cancer incidence and mortality rates in postmenopausal women who had undergone hysterectomy.

Joyce F. Liu, MD, MPH
Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

May 23rd 2024

Timothy Yap, MBBS, PhD, FRCP
First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

May 21st 2024

Emil Lou, MD, PhD, FACP, of the University of Minnesota Medical School
Prognostic Study Correlates TSP and Clinical Outcomes in High-Grade Serous Ovarian Cancer

May 17th 2024

Emil Lou, MD, PhD, FACP, of University of Minnesota Medical School
TSP May Predict Chemoresistance and Survival Outcomes in Ovarian Cancer

May 8th 2024

Video Series
Video Interviews
Podcasts
Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
Latest CME Events & Activities

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

More News